体外研究 (In Vitro) |
IGM-8444 可强效结合 Colo205 结直肠癌细胞 (EC50 = 170 ng/mL) 和 H-EMC-SS 软骨肉瘤细胞 (EC50 = 64 ng/mL)。 IGM-8444 (24 h) 可强效诱导 Colo205 结直肠癌细胞 (IC50 = 1.1 ng/mL) 和 H-EMC-SS 软骨肉瘤细胞 (IC50 = 0.32 ng/mL) 产生细胞毒性。 IGM-8444 (1 μg/mL; 0.5-6 h) 可在 Colo205 结直肠癌细胞和 H-EMC-SS 软骨肉瘤细胞中快速且强效激活 caspase-3/7、caspase-8 和 caspase-9。 IGM-8444 (1 μg/mL; 1-6 h) 处理 6 小时后,可诱导 23%的 Colo205 结直肠癌细胞和 15%的 H-EMC-SS 软骨肉瘤细胞发生早期凋亡。 IGM-8444 (72 h) 在 HCT15 结直肠癌细胞、NCI-H2228 非小细胞肺癌细胞和 MV-411 急性髓系白血病细胞中,与化疗制剂及 ABT-199 (MS-S50888) 表现出协同细胞毒性,其最大 Bliss 评分范围为 16.8 至 53.4。
Apoptosis Analysis
| Cell Line: |
Colo205 colorectal cancer cells, H-EMC-SS chondrosarcoma cells |
| Concentration: |
1 μg/mL |
| Incubation Time: |
1, 3, 6 h |
| Result: |
Induced early apoptosis in 23% of Colo205 cells and 15% of H-EMC-SS cells after 6 hours of treatment. Showed significantly more early apoptosis induction than the corresponding anti-DR5 IgG (4% and 2% early apoptotic cells for Colo205 and H-EMC-SS, respectively), which was similar to isotype controls. |
|
体内研究 (In Vivo) |
IGM-8444 (0.3-20 mg/kg;静脉注射;单次给药或隔日一次;共 11 剂) 可剂量依赖性地抑制小鼠体内 Colo205 结直肠肿瘤的生长。 IGM-8444 (5 mg/kg;静脉注射;每 2 天 1 次;共 11 剂) 可在 NCI-H2122 非小细胞肺癌异种移植物中诱导 101% 的 TGI,将中位无事件生存期延长 40 天。 IGM-8444 (0.3-10 mg/kg;静脉注射;隔日一次) 可在 GXF251 胃癌 PDX 模型中诱导强效、持续的肿瘤消退。 IGM-8444 (5 mg/kg;静脉注射;隔日一次;共 7 次给药) 与 irinotecan (MS-O02109)、5-FU (HY-90006) 或 Paclitaxel (HY-B0015) 联合使用时,可增强 Colo205 结直肠癌异种移植模型中的抗肿瘤效力。 IGM-8444 (5 mg/kg;静脉注射;每两天一次;共 11 剂) 联合 ABT-199 可在 DOHH-2 非霍奇金淋巴瘤异种移植物中诱导 102% 的 TGI 并延长小鼠生存期。
| Animal Model: |
Crl:NU (Ncr)-Foxn1nu (female, 8-12-weeks-old, subcutaneous implantation of 2×106 Colo205 cells) |
| Dosage: |
0.3, 1, 3 and 10 mg/kg (tumor growth inhibition); 0.3, 1, 3, 10 and 20 mg/kg (biomarker analysis) |
| Administration: |
i.v.; every other day; 11 doses (tumor growth inhibition); i.v.; single dose (biomarker analysis) |
| Result: |
Induced 23%, 29%, 75%, and 84% tumor growth inhibition (TGI) on day 22 at doses of 0.3, 1, 3, and 10 mg/kg, respectively. Increased serum M30 up to 10-fold and M65 up to 5-fold in a dose-dependent manner 24 hours after single doses. |
| Animal Model: |
Crl:NU (Ncr)-Foxn1nu (female, 8-12-weeks-old, subcutaneous implantation of 107 NCI-H2122 cells) |
| Dosage: |
5 mg/kg |
| Administration: |
i.v.; every other day; 11 doses (tumor growth and survival); i.v.; single dose (biomarker analysis) |
| Result: |
Induced 101% TGI on day 26, with 5/10 animals achieving a partial response (PR). Extended median event-free survival by 40 days compared with vehicle. Significantly elevated cleaved caspase-3 (CC3) staining in tumor tissue 24 hours after a single dose. |
| Animal Model: |
NMRI nude (female, 5-7-weeks-old, subcutaneous implantation of 3-4 mm GXF251 PDX tumor fragments) |
| Dosage: |
0.3, 1, 3 and 10 mg/kg (dose-dependent study); 5 mg/kg (fixed dose, different tumor sizes) |
| Administration: |
i.v.; every other day; 7 doses (fixed dose); i.v.; every other day (dose-dependent study); i.v.; weekly (weekly dosing study) |
| Result: |
Induced 112% TGI on day 46 at 5 mg/kg every other day for 7 doses, with 8/10 complete responses (CR), 2/10 partial responses (PR), 7/10 event-free animals, and 6/10 tumor-free survivors (TFS) at day 99. Elevated serum M30 10-fold and M65 6-fold 24 hours post-treatment. Induced 30%, 55%, 101%, and 99% TGI on day 59 at doses of 0.3, 1, 3, and 10 mg/kg every other day, respectively, with 2/7 tumor-free animals in the 10 mg/kg group at day 100. Induced 58% and 102% TGI on day 28 with weekly dosing of 1 and 10 mg/kg, respectively. Induced 112%, 103%, and 101% TGI on day 32 when dosed into tumors with initial volumes of 100, 300, or 500 mm3, respectively. |
| Animal Model: |
Crl:NU (Ncr)-Foxn1nu (female, 8-12-weeks-old, subcutaneous implantation of 2×106 Colo205 cells) |
| Dosage: |
5 mg/kg (single agent); 5 mg/kg + 100 mg/kg irinotecan; 5 mg/kg + 100 mg/kg 5-FU; 5 mg/kg + 25 mg/kg paclitaxel |
| Administration: |
i.v.; every other day; 7 doses (IGM-8444); i.p.; weekly; 3 weeks (Irinotecan, 5-FU); i.v.; every other day; 5 doses (Paclitaxel) |
| Result: |
Induced 70%-76% TGI as a single agent at 5 mg/kg. Combination with Irinotecan induced 103% TGI with 2/10 PRs and extended median event-free survival by 42 days compared with vehicle. Combination with 5-FU induced 104% TGI with 3/10 PRs and 1/10 CR/TFS, without additional toxicity compared with 5-FU alone. Combination with paclitaxel increased CR rate from 30% (Paclitaxel alone) to 100%, with 8/10 animals tumor-free at day 100 compared with 2/10 in the Paclitaxel-only group. |
| Animal Model: |
Fox Chase SCID, CB17/Icr-Prkdcscid/IcrIcoCrl (female, 9-weeks-old, subcutaneous implantation of 107 DOHH-2 cells) |
| Dosage: |
5 mg/kg (single agent); 5 mg/kg + 100 mg/kg ABT-199 |
| Administration: |
i.v.; every other day; 11 doses (IGM-8444); p.o.; daily; 21 days (ABT-199) |
| Result: |
Induced 45% TGI as a single agent at 5 mg/kg. Combination with ABT-199 induced 102% TGI with 3/10 PRs and 2/10 CRs. Significantly extended median event-free survival compared with vehicle or ABT-199 alone. |
|